Article
Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype.
Circulation - 17 Apr 2001
März W, Scharnagl H, Abletshauser C, Hoffmann M M, Berg A, Keul J, Wieland H, Baumstark M W
Abstract excerpt
BACKGROUND: Although HMG-CoA reductase inhibitors (HMGRIs) are effective lipid-lowering agents, it remains controversial whether these agents also lower dense LDL (dLDL), a predominance of which is considered to contribute to the atherogenicity of the metabolic syndrome. METHODS AND RESULTS: In a multicenter, double-blind, randomized, placebo-controlled study, we determined the effect of the HMGRI fluvastatin on...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.